Locally Advanced Rectal Cancer Clinical Trials

19 recruiting

Locally Advanced Rectal Cancer Trials at a Glance

29 actively recruiting trials for locally advanced rectal cancer are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Candiolo. Lead sponsors running locally advanced rectal cancer studies include Fudan University, Fondazione del Piemonte per l'Oncologia, and Beijing Friendship Hospital.

Browse locally advanced rectal cancer trials by phase

Treatments under study

About Locally Advanced Rectal Cancer Clinical Trials

Looking for clinical trials for Locally Advanced Rectal Cancer? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Rectal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Rectal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 2

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer
Jinhua Central Hospital37 enrolled1 locationNCT06204094
Recruiting

Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Beijing Friendship Hospital60 enrolled1 locationNCT07393048
Recruiting
Phase 2

A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

Locally Advanced Rectal Cancer
Chinese PLA General Hospital44 enrolled1 locationNCT07527026
Recruiting
Not Applicable

Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients

Lung CancerHead and Neck Squamous Cell CarcinomaLocally Advanced Rectal Cancer
Fondazione del Piemonte per l'Oncologia52 enrolled1 locationNCT07514754
Recruiting
Phase 2

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University192 enrolled1 locationNCT06281405
Recruiting

GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients

Lung CancerHead and Neck Squamous Cell CarcinomaLocally Advanced Rectal Cancer
Fondazione del Piemonte per l'Oncologia110 enrolled1 locationNCT07511413
Recruiting
Phase 2

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Locally Advanced Rectal Cancer With Liver Metastases
Fujian Cancer Hospital42 enrolled2 locationsNCT06787183
Recruiting
Phase 1

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Akamis Bio30 enrolled6 locationsNCT06459869
Recruiting
Phase 1

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer
University of Miami25 enrolled1 locationNCT05412082
Recruiting
Phase 2

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK)

pMMR/MSS Locally Advanced Rectal Cancer
Dechang Diao86 enrolled1 locationNCT07005570
Recruiting
Phase 2

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
First Affiliated Hospital of Zhejiang University116 enrolled1 locationNCT06864013
Recruiting
Phase 2

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
First Affiliated Hospital of Wenzhou Medical University30 enrolled1 locationNCT07347951
Recruiting
Not Applicable

Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer

Older PeopleLocally Advanced Rectal Cancer
Jules Bordet Institute230 enrolled19 locationsNCT06052332
Recruiting

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
National Cancer Institute, Naples50 enrolled2 locationsNCT07269249
Recruiting
Phase 2

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University138 enrolled1 locationNCT07150949
Recruiting
Phase 2

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital90 enrolled1 locationNCT07057089
Recruiting
Phase 2

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

Locally Advanced Rectal Cancer (LARC)
brenner baruch134 enrolled2 locationsNCT06940388
Recruiting
Phase 2

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences228 enrolled2 locationsNCT07040098
Recruiting
Phase 3

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

RadiotherapyImmunotherapyLocally Advanced Rectal Cancer (LARC)+2 more
West China Hospital184 enrolled1 locationNCT07020247
Recruiting
Not Applicable

Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Centre Hospitalier Universitaire Saint Pierre20 enrolled1 locationNCT06761287